| MeSH term | MeSH ID | Detail |
|---|---|---|
| Heart Failure | D006333 | 36 associated lipids |
| Arthritis, Rheumatoid | D001172 | 3 associated lipids |
| Osteitis | D010000 | 10 associated lipids |
| Coronary Disease | D003327 | 70 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Hip Fractures | D006620 | 2 associated lipids |
| Osteolysis | D010014 | 8 associated lipids |
| Hypothyroidism | D007037 | 32 associated lipids |
| Osteoarthritis, Hip | D015207 | 4 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Daroszewska A et al. | Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. | 2004 | J. Bone Miner. Res. | pmid:15312251 |
| Liu JM et al. | [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75]. | 2004 | Zhonghua Nei Ke Za Zhi | pmid:15312444 |
| Jacobson A et al. | Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15313187 |
| Ishida M and Amano S | Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. | 2004 | J. Bone Miner. Metab. | pmid:15316862 |
| Jeffcoate W | Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? | 2004 | Diabetologia | pmid:15322748 |
| Liu Z et al. | Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. | 2004 | Protein Pept. Lett. | pmid:15327363 |
| Politou M et al. | Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). | 2004 | Br. J. Haematol. | pmid:15327520 |
| Erdogan B et al. | Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. | 2004 | Neurol. Res. | pmid:15327755 |
| Wada N et al. | Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. | 2004 | Bone | pmid:15336598 |
| Amato G et al. | High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. | 2004 | Bone | pmid:15336617 |
| Ono Y et al. | Suppressive effect of Kanzo-bushi-to, a Kampo medicine, on collagen-induced arthritis. | 2004 | Biol. Pharm. Bull. | pmid:15340228 |
| Sato N et al. | MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. | 2004 | J. Exp. Med. | pmid:15353553 |
| Wang L et al. | Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34). | 2004 | J. Bone Miner. Res. | pmid:15355561 |
| Nyambo R et al. | Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. | 2004 | J. Bone Miner. Res. | pmid:15355567 |
| Roux S and Mariette X | The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. | 2004 | Leuk. Lymphoma | pmid:15359989 |
| Wittrant Y et al. | RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. | 2004 | Biochim. Biophys. Acta | pmid:15363860 |
| Miyazaki T et al. | Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. | 2004 | J. Cell. Biochem. | pmid:15372622 |
| Tian QX and Huang GY | [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts]. | 2004 | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | pmid:15379268 |
| Nitta K et al. | Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. | 2004 | Am. J. Kidney Dis. | pmid:15384019 |
| Mizutani Y et al. | Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. | 2004 | Cancer | pmid:15386310 |
| Burton DW et al. | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. | 2005 | Prostate | pmid:15389781 |
| Abu-Amer Y et al. | TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. | 2004 | J. Cell. Biochem. | pmid:15389885 |
| Smith MD | Comment on review on T cells in bone biology. | 2004 | Rheumatology (Oxford) | pmid:15448222 |
| Liu JM et al. | Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. | 2005 | Calcif. Tissue Int. | pmid:15455183 |
| Boabaid F et al. | Leucine-rich amelogenin peptide: a candidate signaling molecule during cementogenesis. | 2004 | J. Periodontol. | pmid:15455742 |
| Collantes Estévez E and González DomÃnguez J | [Bone Paget's disease in the young adult]. | 2004 | Rev Clin Esp | pmid:15456600 |
| Wise GE et al. | Regulation of secretion of osteoprotegerin in rat dental follicle cells. | 2004 | Eur. J. Oral Sci. | pmid:15458504 |
| Kitaura H et al. | Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. | 2004 | J. Immunol. | pmid:15470024 |
| Notoya M et al. | Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15474477 |
| Yip KH et al. | Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. | 2004 | J. Bone Miner. Res. | pmid:15476591 |
| Dai SM et al. | Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. | 2004 | Ann. Rheum. Dis. | pmid:15479886 |
| Wang JC et al. | Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). | 2004 | Exp. Hematol. | pmid:15504545 |
| Boabaid F et al. | The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts. | 2004 | J. Periodontol. | pmid:15515341 |
| Franck H et al. | Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. | 2004 | J. Rheumatol. | pmid:15517638 |
| Ueland T | Bone metabolism in relation to alterations in systemic growth hormone. | 2004 | Growth Horm. IGF Res. | pmid:15519248 |
| Vidal K et al. | Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. | 2004 | Am. J. Physiol. Gastrointest. Liver Physiol. | pmid:15521102 |
| Chen Q et al. | Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. | 2004 | Horm. Metab. Res. | pmid:15523591 |
| Grigorie D et al. | Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. | 2003 | Rom J Intern Med | pmid:15526523 |
| Saidenberg-Kermanac'h N et al. | TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. | 2004 | Bone | pmid:15542046 |
| Ueland T et al. | Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. | 2004 | J. Am. Coll. Cardiol. | pmid:15542278 |
| Demer LL and Abedin M | Skeleton key to vascular disease. | 2004 | J. Am. Coll. Cardiol. | pmid:15542279 |
| Franchimont N et al. | Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. | 2004 | Clin. Exp. Immunol. | pmid:15544627 |
| Ketteler M et al. | "Missing" inhibitors of calcification: general aspects and implications in renal failure. | 2005 | Pediatr. Nephrol. | pmid:15549415 |
| Ichinose Y et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading. | 2004 | Calcif. Tissue Int. | pmid:15549649 |
| Kanzaki H et al. | Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement. | 2004 | J. Dent. Res. | pmid:15557398 |
| Zhang X et al. | Synovial fibroblasts infected with Salmonella enterica serovar Typhimurium mediate osteoclast differentiation and activation. | 2004 | Infect. Immun. | pmid:15557643 |
| Theoleyre S et al. | The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. | 2004 | Cytokine Growth Factor Rev. | pmid:15561602 |
| Mori T et al. | RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. | 2004 | Nucleic Acids Res. | pmid:15562003 |
| Oh ES et al. | Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. | 2005 | Metab. Clin. Exp. | pmid:15562379 |
| Ling JQ and Li JP | [Insulin-like growth factor-II and basic fibroblast growth factor affect periodontal ligament cells expressing osteoprotegerin in vitro]. | 2004 | Hua Xi Kou Qiang Yi Xue Za Zhi | pmid:15562643 |
| Collin-Osdoby P | Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. | 2004 | Circ. Res. | pmid:15564564 |
| Neville-Webbe HL et al. | Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. | 2004 | Breast Cancer Res. Treat. | pmid:15567943 |
| Rhee EJ et al. | Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. | 2005 | Clin. Sci. | pmid:15569000 |
| Fang TY et al. | [Serum osteoprotegrin and serum bone gamma-carboxyglutamine acid-containing protein are correlated with bone mineral density in normal women]. | 2004 | Zhonghua Yi Xue Za Zhi | pmid:15569454 |
| Atkins GJ et al. | Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. | 2005 | J. Cell. Physiol. | pmid:15573398 |
| Masui T et al. | Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. | 2005 | Biomaterials | pmid:15576143 |
| Herrmann M and Herrmann W | The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. | 2004 | Clin. Chem. Lab. Med. | pmid:15576300 |
| Jono S | [Risk factors of atherosclerosis in end-stage renal disease patients]. | 2004 | Clin Calcium | pmid:15576949 |
| Shimizu M and Tamura T | [Regulation of bone mineralization by parathyroid hormone]. | 2004 | Clin Calcium | pmid:15577058 |
| Ogata H et al. | [Prophylaxis and treatment of adynamic bone]. | 2004 | Clin Calcium | pmid:15577107 |
| Manganelli P et al. | OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? | 2005 | Clin. Rheumatol. | pmid:15583970 |
| Wang L et al. | Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. | 2005 | Am. J. Physiol. Endocrinol. Metab. | pmid:15585587 |
| Byrne FR et al. | CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. | 2005 | Gut | pmid:15591508 |
| Lee CK et al. | Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. | 2004 | Arthritis Rheum. | pmid:15593184 |
| Zhang D et al. | [Expression of OPG and RANKL at protein level in human periodontal ligament cells and the effect of 1alpha,25(OH)(2) vitamin D(3) on the secretion of OPG protein in vitro]. | 2004 | Beijing Da Xue Xue Bao | pmid:15605102 |
| Rajzbaum G et al. | French women, fractures and aortic calcifications. | 2005 | J. Intern. Med. | pmid:15606383 |
| Chondrogianni N et al. | Cloning of differentially expressed genes in skin fibroblasts from centenarians. | 2004 | Biogerontology | pmid:15609104 |
| Martinetti A et al. | Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. | 2004 | Endocr. Relat. Cancer | pmid:15613451 |
| Whyte MP and Mumm S | Heritable disorders of the RANKL/OPG/RANK signaling pathway. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615493 |
| Hofbauer LC et al. | The OPG/RANKL/RANK system in metabolic bone diseases. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615494 |
| Ritchlin CT et al. | RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615495 |
| Clohisy DR and Mantyh PW | Bone cancer pain and the role of RANKL/OPG. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615497 |
| Sakai A et al. | Osteoclast development in immobilized bone is suppressed by parathyroidectomy in mice. | 2005 | J. Bone Miner. Metab. | pmid:15616888 |
| Sasaki N et al. | Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). | 2005 | J. Bone Miner. Metab. | pmid:15616893 |
| Belibasakis GN et al. | The cytolethal distending toxin induces receptor activator of NF-kappaB ligand expression in human gingival fibroblasts and periodontal ligament cells. | 2005 | Infect. Immun. | pmid:15618171 |
| Liu XH et al. | Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. | 2005 | Endocrinology | pmid:15618359 |
| Cao JJ et al. | Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. | 2005 | J. Bone Miner. Res. | pmid:15619667 |
| Liu PY et al. | A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators. | 2005 | J. Clin. Endocrinol. Metab. | pmid:15623811 |
| Zehnder AF et al. | Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. | 2005 | Laryngoscope | pmid:15630389 |
| Kees M et al. | Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera. | 2005 | Thromb. Haemost. | pmid:15630493 |
| Grzegorzewska AE and MÅ‚ot M | Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631341 |
| Grzegorzewska AE and MÅ‚ot M | Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631342 |
| Mochizuki S et al. | [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis]. | 2005 | Clin Calcium | pmid:15632471 |
| Naumnik W et al. | Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15638385 |
| Oh KW et al. | Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. | 2005 | Clin. Endocrinol. (Oxf) | pmid:15638876 |
| Marotte H et al. | Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. | 2005 | Arthritis Res. Ther. | pmid:15642135 |
| Katsuyama H et al. | Menaquinone-7 regulates the expressions of osteocalcin, OPG, RANKL and RANK in osteoblastic MC3T3E1 cells. | 2005 | Int. J. Mol. Med. | pmid:15647836 |
| Altun A et al. | Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. | 2004 | J. Endocrinol. Invest. | pmid:15648548 |
| Matayoshi T et al. | Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells. | 2005 | Biochem. Biophys. Res. Commun. | pmid:15649411 |
| Lukić IK et al. | Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1. | 2005 | Clin. Exp. Immunol. | pmid:15654822 |
| Subramaniam M et al. | TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. | 2005 | Mol. Cell. Biol. | pmid:15657444 |
| Sato K | [Osteoclast-activating factors (OAF)]. | 2004 | Nippon Rinsho | pmid:15658306 |
| Kiviranta R et al. | Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. | 2005 | Bone | pmid:15664014 |
| Avbersek-Luznik I et al. | Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? | 2005 | Nephrol. Dial. Transplant. | pmid:15665031 |
| Bhatia P et al. | Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. | 2005 | Clin. Cancer Res. | pmid:15671541 |
| Kiefer JA et al. | The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. | 2004 | Clin. Exp. Metastasis | pmid:15672862 |
| Rassi CM et al. | Modulation of osteoclastogenesis in porcine bone marrow cultures by quercetin and rutin. | 2005 | Cell Tissue Res. | pmid:15688188 |
| Haynes DR | Bone lysis and inflammation. | 2004 | Inflamm. Res. | pmid:15693607 |
| Olesen P et al. | Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. | 2005 | Diabetologia | pmid:15700136 |
| Silvestrini G et al. | Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. | 2005 | J. Mol. Histol. | pmid:15704000 |